home / stock / onc:cc / onc:cc quote
Last: | $1.52 |
---|---|
Change Percent: | -1.94% |
Open: | $1.55 |
Close: | $1.55 |
High: | $1.55 |
Low: | $1.48 |
Volume: | 36,421 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.52 | $1.55 | $1.55 | $1.55 | $1.48 | 36,421 | 08-02-2022 |
$1.75 | $1.75 | $1.75 | $1.8 | $1.75 | 48,702 | 05-06-2022 |
$1.79 | $1.85 | $1.79 | $1.85 | $1.75 | 26,478 | 05-05-2022 |
$1.85 | $1.75 | $1.85 | $1.85 | $1.74 | 32,801 | 05-04-2022 |
$1.72 | $1.76 | $1.72 | $1.82 | $1.71 | 49,625 | 05-03-2022 |
$1.78 | $1.71 | $1.78 | $1.8 | $1.71 | 40,792 | 05-02-2022 |
$1.72 | $1.68 | $1.72 | $1.72 | $1.67 | 28,579 | 04-29-2022 |
$1.68 | $1.7 | $1.68 | $1.7 | $1.61 | 63,889 | 04-28-2022 |
$1.72 | $1.72 | $1.72 | $1.75 | $1.71 | 31,269 | 04-27-2022 |
$1.72 | $1.72 | $1.72 | $1.74 | $1.7 | 39,667 | 04-26-2022 |
$1.75 | $1.75 | $1.75 | $1.76 | $1.72 | 22,762 | 04-25-2022 |
$1.73 | $1.71 | $1.73 | $1.78 | $1.71 | 57,587 | 04-22-2022 |
$1.75 | $1.81 | $1.75 | $1.81 | $1.75 | 46,431 | 04-21-2022 |
$1.81 | $1.76 | $1.81 | $1.82 | $1.76 | 63,298 | 04-20-2022 |
$1.82 | $1.88 | $1.82 | $1.88 | $1.76 | 88,988 | 04-19-2022 |
$1.84 | $1.85 | $1.84 | $1.88 | $1.82 | 61,847 | 04-18-2022 |
$1.9 | $1.86 | $1.9 | $1.93 | $1.78 | 120,531 | 04-15-2022 |
$1.9 | $1.86 | $1.9 | $1.93 | $1.78 | 120,468 | 04-14-2022 |
$1.98 | $1.96 | $1.98 | $1.98 | $1.94 | 16,380 | 04-13-2022 |
$1.95 | $1.98 | $1.95 | $1.98 | $1.93 | 19,664 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...